Advances of GADD45b in hepatic glucose and lipid metabolism

doi:10.3969/j.issn.1674-8115.2024.10.014

Abstract

Abstract:

Growth arrest and DNA damage-inducible 45b (GADD45b) was initially discovered to be involved in processes such as cell cycle arrest, differentiation and apoptosis. It is an important signal regulatory molecule in cells, responsible for signal transduction under various physiological or environmental stimuli. The GADD45b gene belongs to the GADD45 gene family. This gene is commonly expressed in human and fetal tissues, but the expression is tissue-specific, with high expression in the liver and bone marrow. The GADD45b protein is a small, evolutionarily conserved acidic protein distributed in both the cytoplasm and nucleus. Research has shown that GADD45b is closely associated with signaling pathways such as p38/MAPK and TGFβ/Smad3, and it has functions including improving tissue fibrosis and inflammation progression, inhibiting cell autophagy, and enhancing neural function recovery. GADD45b plays a significant role in tumors, innate immunity, neurological diseases, and disorders of hepatic glucose and lipid metabolism. The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing year by year in China and has become a serious public health issue in the country. Disorders in hepatic glucose and lipid metabolism are major causes of NAFLD. Multiple studies have shown that GADD45b gene and protein exhibit abnormal expression in liver diseases with hepatic glucose and lipid metabolism disorders. Previous research has found that GADD45b can increase the stability of the FoxO1 protein in hepatocytes, and enhance the expression of PGC1a, thereby promoting hepatic gluconeogenesis. Additionally, GADD45b can inhibit fatty acid transport in hepatocytes by binding to FABP1 and reduce hepatic steatosis by interacting with HSP72 protein. Therefore, the roles of GADD45b in promoting hepatic gluconeogenesis, inhibiting fatty acid transport, and reducing steatosis may form the basis for research into treatments for hepatic glucose and lipid metabolism disorders and liver diseases. This paper reviews the characteristics and functions of the GADD45b protein, as well as recent advances in the study of hepatic glucose and lipid metabolism and liver diseases, aiming to provide reference for further GADD45b research.

Key words: growth arrest and DNA damage inducible 45b (GADD45b), glycolipid metabolism, metabolic disorder, non-alcoholic fatty liver disease

CLC Number:

R575.5

WANG Renjie, HUA Hui, ZHU ChaoYu, WEI Li. Advances of GADD45b in hepatic glucose and lipid metabolism[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1316-1322.

Figures/Tables 4

TrendMD

References 48

1	BEADLING C, JOHNSON K W, SMITH K A. Isolation of interleukin 2-induced immediate-early genes[J]. Proc Natl Acad Sci USA, 1993, 90(7): 2719-2723.
2	ABDOLLAHI A, LORD K A, HOFFMAN-LIEBERMANN B, et al. Sequence and expression of a cDNA encoding MyD118: a novel myeloid differentiation primary response gene induced by multiple cytokines[J]. Oncogene, 1991, 6(1): 165-167.
3	LIEBERMANN D A, HOFFMAN B. Gadd45 in stress signaling[J]. J Mol Signal, 2008, 3: 15.
4	KEARSEY J M, COATES P J, PRESCOTT A R, et al. Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1[J]. Oncogene, 1995, 11(9): 1675-1683.
5	HILDESHEIM J, BULAVIN D V, ANVER M R, et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53[J]. Cancer Res, 2002, 62(24): 7305-7315.
6	SULTAN F A, SAWAYA B E. Gadd45 in neuronal development, function, and injury[J]. Adv Exp Med Biol, 2022, 1360: 117-148.
7	TAMURA R E, DE VASCONCELLOS J F, SARKAR D, et al. GADD45 proteins: central players in tumorigenesis[J]. Curr Mol Med, 2012, 12(5): 634-651.
8	ZAIDI M R, LIEBERMANN D A. Gadd45 in senescence[J]. Adv Exp Med Biol, 2022, 1360: 109-116.
9	ZHAN Q, LORD K A, ALAMO I Jr, et al. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth[J]. Mol Cell Biol, 1994, 14(4): 2361-2371.
10	HOFFMAN B, LIEBERMANN D A. Role of gadd45 in myeloid cells in response to hematopoietic stress[J]. Blood Cells Mol Dis, 2007, 39(3): 344-347.
11	ZHANG W, BAE I, KRISHNARAJU K, et al. CR6: a third member in the MyD118 and Gadd45 gene family which functions in negative growth control[J]. Oncogene, 1999, 18(35): 4899-4907.
12	FAGERBERG L, HALLSTRÖM B M, OKSVOLD P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics[J]. Mol Cell Proteomics, 2014, 13(2): 397-406.
13	BALLIET A G, HATTON K S, HOFFMAN B, et al. Comparative analysis of the genetic structure and chromosomal location of the murine MyD118 (Gadd45β) gene[J]. DNA Cell Biol, 2001, 20(4): 239-247.
14	VAIRAPANDI M, BALLIET A G, HOFFMAN B, et al. GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress[J]. J Cell Physiol, 2002, 192(3): 327-338.
15	SMITH M L, CHEN I T, ZHAN Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen[J]. Science, 1994, 266(5189): 1376-1380.
16	SHI Y L, WANG J Y, HUANG G, et al. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma[J]. Hepatol Int, 2022, 16(4): 906-917.
17	KEIL E, HÖCKER R, SCHUSTER M, et al. Phosphorylation of Atg5 by the Gadd45β-MEKK4-p38 pathway inhibits autophagy[J]. Cell Death Differ, 2013, 20(2): 321-332.
18	XUE M, SUN H X, XU R, et al. GADD45B promotes glucose-induced renal tubular epithelial-mesenchymal transition and apoptosis via the p38 MAPK and JNK signaling pathways[J]. Front Physiol, 2020, 11: 1074.
19	SHEN X Y, SHI S H, LI H, et al. The role of Gadd45b in neurologic and neuropsychiatric disorders: an overview[J]. Front Mol Neurosci, 2022, 15: 1021207.
20	DENG K P, FAN Y X, LIANG Y X, et al. FTO-mediated demethylation of GADD45B promotes myogenesis through the activation of p38 MAPK pathway[J]. Mol Ther Nucleic Acids, 2021, 26: 34-48.
21	MOON S J, KIM J H, CHOI Y K, et al. Ablation of Gadd45β ameliorates the inflammation and renal fibrosis caused by unilateral ureteral obstruction[J]. J Cell Mol Med, 2020, 24(15): 8814-8825.
22	ZHANG K M, ZHANG Q B, DENG J, et al. ALK5 signaling pathway mediates neurogenesis and functional recovery after cerebral ischemia/reperfusion in rats via Gadd45b[J]. Cell Death Dis, 2019, 10(5): 360.
23	SHAH A, WONDISFORD F E. Gluconeogenesis flux in metabolic disease[J]. Annu Rev Nutr, 2023, 43: 153-177.
24	MOUCHIROUD L, EICHNER L J, SHAW R J, et al. Transcriptional coregulators: fine-tuning metabolism[J]. Cell Metab, 2014, 20(1): 26-40.
25	FUHRMEISTER J, ZOTA A, SIJMONSMA T P, et al. Fasting-induced liver GADD45β restrains hepatic fatty acid uptake and improves metabolic health[J]. EMBO Mol Med, 2016, 8(6): 654-669.
26	KIM H, LEE D S, AN T H, et al. GADD45β regulates hepatic gluconeogenesis via modulating the protein stability of FoxO1[J]. Biomedicines, 2021, 9(1): 50.
27	WU L, JIAO Y, LI Y, et al. Hepatic Gadd45β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1α[J]. J Exp Med, 2021, 218(5): e20201475.
28	LING C, RÖNN T. Epigenetics in human obesity and type 2 diabetes[J]. Cell Metab, 2019, 29(5): 1028-1044.
29	DONG Y X, MA N N, FAN L, et al. GADD45β stabilized by direct interaction with HSP72 ameliorates insulin resistance and lipid accumulation[J]. Pharmacol Res, 2021, 173: 105879.
30	LOOMBA R, FRIEDMAN S L, SHULMAN G I. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564.
31	ZHANG L T, LIU T J, HU C Z, et al. Proteome analysis identified proteins associated with mitochondrial function and inflammation activation crucially regulating the pathogenesis of fatty liver disease[J]. BMC Genomics, 2021, 22(1): 640.
32	WU J K, SHAO X H, SHEN J X, et al. Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells[J]. Int J Biol Sci, 2022, 18(14): 5438-5458.
33	MAN S, DENG Y H, MA Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023, 165(4): 1025-1040.
34	LIN H P, YIP T C, ZHANG X R, et al. Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(2): 573-584.
35	YOUNOSSI Z M, HARRING M, YOUNOSSI Y, et al. The impact of NASH to liver transplantations with hepatocellular carcinoma in the United States[J]. Clin Gastroenterol Hepatol, 2022, 20(12): 2915-2917.e1.
36	ZHANG Z H, WANG S H, ZHU Z W, et al. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies[J]. Comput Biol Med, 2023, 157: 106724.
37	YIP T C, FAN J G, WONG V W. China's fatty liver crisis: a looming public health emergency[J]. Gastroenterology, 2023, 165(4): 825-827.
38	JIANG Y, XIANG C, ZHONG F, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis[J]. Theranostics, 2021, 11(1): 361-378.
39	TZENG H T, CHYUAN I T, CHEN W Y. Shaping of innate immune response by fatty acid metabolite palmitate[J]. Cells, 2019, 8(12): 1633.
40	QIU W H, DAVID D, ZHOU B S, et al. Down-regulation of growth arrest DNA damage-inducible gene 45β expression is associated with human hepatocellular carcinoma[J]. Am J Pathol, 2003, 162(6): 1961-1974.
41	XIA H P, LEE K W, CHEN J X, et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib[J]. Cell Death Discov, 2017, 3: 17058.
42	OU D L, SHEN Y C, YU S L, et al. Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells[J]. Cancer Res, 2010, 70(22): 9309-9318.
43	HOU X J, ZHAO Q D, JING Y Y, et al. Methylation mediated Gadd45β enhanced the chemosensitivity of hepatocellular carcinoma by inhibiting the stemness of liver cancer cells[J]. Cell Biosci, 2017, 7: 63.
44	GONG L Q, CAI L Q, LI G D, et al. GADD45B facilitates metastasis of ovarian cancer through epithelial-mesenchymal transition[J]. Onco Targets Ther, 2021, 14: 255-269.
45	CHEN L, KARISMA V W, LIU H W, et al. MicroRNA-300: a transcellular mediator in exosome regulates melanoma progression[J]. Front Oncol, 2019, 9: 1005.
46	NAPOLIONI V, BIANCONI F, POTENZA R, et al. Genome-wide expression of the residual lung reacting to experimental Pneumonectomy[J]. BMC Genomics, 2021, 22(1): 881.
47	WANG Q, WU W H, GAO Z, et al. GADD45B is a potential diagnostic and therapeutic target gene in chemotherapy-resistant prostate cancer[J]. Front Cell Dev Biol, 2021, 9: 716501.
48	YAO Z Y, CHEN Y, CAO W H, et al. Chromatin-modifying drugs and metabolites in cell fate control[J]. Cell Prolif, 2020, 53(11): e12898.

[1]	BIAN Shu, YU Qian, LIU Liangming. Research progress in the role of endo cannabinoid system in liver diseases [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1299-1306.
[2]	BENEDICK Jun Er Chin, SON Peng, ZHANG Yifan, WANG Junqing, GUO Simin. Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1585-1590.
[3]	LIU Junjun, LU Sumei, ZHANG Bingyang, LI Yongqing, MA Wanshan. Analysis of m⁶A methylation expression profiles in liver tissue of high-fat diet-induced mouse models of NAFLD [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1227-1235.
[4]	Xiaowen ZHANG, Yi WANG, Chan ZHANG, Di ZHANG, Hang YUN, Di HUANG. Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 150-157.
[5]	Jiang YUE, Yong ZHOU, Hua XU, Wen LIU, Xiao-feng HAN, Qing MAO, Ji-dong ZHANG, Jing MA, Han-dong JIANG, Wei LIU. Characteristic analysis and comparison of glycolipid metabolism in patients with coronavirus disease 2019 in common condition and severe cases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 355-359.
[6]	Chao SANG, Dan-dan LIANG, Guo-xiang XIE, Wei JIA, Tian-lu CHEN. Progress in serological noninvasive diagnostic methods for non-alcoholic fatty liver disease [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 112-117.
[7]	GUO Yi-qiong, WU Qiong, WU Ya-ting, GAO Lu-lu, YANG Jian-jun. Effect of Lycium barbarum polysaccharide and aerobic exercise on rats with non-alcoholic fatty liver disease and its mechanism [J]. , 2020, 40(1): 30-.
[8]	PENG Rong, YANG Li-jun, DENG Mao-lin. Effects of low-carbohydrate diet on body weight and glycolipid metabolism in normal rats and obese rats [J]. , 2020, 40(1): 44-.
[9]	ZHAO Ming-liang1, 2, ZHAO Ai-hua1, ZHENG Xiao-jiao1, JIA Wei1. Role of farnesol X receptor in glycolipid metabolism regulation [J]. , 2019, 39(6): 671-.
[10]	ZHU Fan-fan, YANG Li-zhen. Correlation between the levels of serum thyroid hormones and non-alcoholic fatty liver disease in euthyroid type 2 diabetic patients [J]. , 2018, 38(7): 763-.
[11]	JIAN Chao-hui, BAO Yu-qian. Research progress of autophagy in non-alcoholic fatty liver disease [J]. , 2018, 38(6): 690-.
[12]	YING Chen1, LIU Cai-hong2, HU Jia-an2, JIANG Shi-hu3, XU Zhi-hong2, SUN Jing2. Research on level of serum lipid metabolism related hormones in patients of obstructive sleep apnoea hypoxia syndrome combine with non-alcoholic fatty liver disease [J]. , 2018, 38(10): 1203-.
[13]	HOU Ya-nan, XUAN Li-ping, PENG Kui, DU Rui, XU Yu, CHEN Yu-hong, LU Jie-li, BI Yu-fang, XU Min, WANG Wei-qing, NING Guang . Association between mid-upper arm circumference and non-alcoholic fatty liver disease or insulin resistance in middle-aged and elderly Chinese community population#br# [J]. , 2017, 37(9): 1232-.
[14]	SUN Wen-wen, RUAN Yu-feng， LIAN Peng, YING Chen, HU Jia-an, XU Zhi-hong, SUN Jing. Effects of obstructive sleep apnoea syndrome on non-alcoholic fatty liver disease [J]. , 2016, 36(5): 707-.
[15]	KANG Bing, PENG Chuan, ZUO De-yu, et al. Correlation between secreted frizzled-related protein 5 level and blood lipids in serum of patients with nonalcoholic fatty liver disease [J]. , 2015, 35(5): 694-.